PolyActiva is an Australian-based biotechnology company that has developed a platform technology to deliver drugs to specific sites in the body. The polymeric prodrugs can take various forms, including rod-shaped implants, injectable gels and topical films and the rate of drug delivery can be controlled for up to 12 months.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

news image

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More

Industrial Impact

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

news image

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More

Diagnostics

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

news image

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More
news image

Cell and Gene Therapy

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More
news image

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More
news image

Industrial Impact

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More
news image

Diagnostics

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us